INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect
Open accessAbstract
Importance of the field: Novel approaches are needed for patients with small cell lung cancer (SCLC), as response after relapse is poor with standard therapies. p53 gene mutations often occur, resulting in tumoral protein overexpression and allowing for their recognition by p53-specific cytotoxic T cells.Areas covered in this review: We describe the characteristics and manufacturing of INGN-225, a p53-modified adenovirus-tranduced dendritic cell vaccine, and review available data, to understand INGN-225's role in SCLC treatment. We discuss our pre-clinical, early Phase I/II, and ongoing randomized Phase II studies.What the reader will gain: INGN-225 was well tolerated (all toxicities ≤grade 2) in the Phase I/II trial (54 patients receiving at least 1 dose). Specific anti-p53 immune response was positive in 18/43 (41.8%) patients, with overall post-INGN-225 response observed in 17/33 (51.5%) and immune response data available in 29 (14 positive, 15 negative). Post-INGN-225 response was observed in 11/14 (78.6%) and 5/15 (33%) patients with positive and negative immune responses, respectively.Take home message: INGN-225 is safe, induces a significant immune response, and appears to sensitize SCLC to subsequent chemotherapy. Improvements in immune response induction and understanding the chemotherapy–immunotherapy synergism will determine INGN-225's future role as an anticancer therapy.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
DC-p53 was used as a p53 vaccine with chemotherapy in patients with small cell lung cancer, and objective clinical responses were observed in some patients.
“In researches from Antonia’s and Chiappori’s group, a modified autologous dendritic cells expressing p53 peptides (DC-p53 (254)) was used as a p53 vaccine and applied in combination with chemotherapy in patients with small cell lung cancer (SCLC).595,596 Although objective clinical responses were observed in some patients”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [596]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Jemal, A., Siegel, R. L., Ward, E., Hao, Y., Xu, J., Murray, T., & Thun, M. J. (2008) · CA A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0010 · Cited by 10,184 · see citing works
Almand, B., Clark, J. I., Nikitina, E., van Beynen, J., English, N. R., Knight, S. C., Carbone, D. P., & Gabrilovich, D. I. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.678 · Cited by 1,340 · see citing works
Self-citationMechanisms and functional significance of tumour-induced dendritic-cell defects
Gabrilovich, D. I. (2004) · Nature reviews. Immunology · doi:10.1038/nri1498 · Cited by 1,022 · see citing works
Self-citationvon Pawel, J., Schiller, J. H., Shepherd, F. A., Fields, S. Z., Kleisbauer, J. P., Chrysson, N. G., Stewart, D. J., CLARK, P. I., Palmer, M., Depierre, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.658 · Cited by 968 · see citing works
Gene Therapy for Cancer: What Have We Done and Where Are We Going?
Roth, J. A., & Cristiano, R. J. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.1.21 · Cited by 636 · see citing works
Chapter 8 Use of Recombinant Adenovirus for Metabolic Engineering of Mammalian Cells
Becker, T. C., Noel, R. J., Coats, W. S., Gómèz‐Foix, A. M., Alam, T., Gerard, R. D., & Newgard, C. B. (1994) · Methods in cell biology · doi:10.1016/s0091-679x(08)60603-2 · Cited by 569 · see citing works
Mirza, N. N., Fishman, M., Fricke, I., Dunn, M. W., Neuger, A. M., Frost, T. J., Lush, R. M., Antonia, S. J., & Gabrilovich, D. I. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1690 · Cited by 566 · see citing works
Self-citationOzao-Choy, J., Ma, G., Kao, J., Wang, G. X., Meseck, M., Sung, M., Schwartz, M., Divino, C. M., Pan, P.-Y., & Chen, S.-H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4709 · Cited by 538 · see citing works
Mechanism of Immune Dysfunction in Cancer Mediated by Immature Gr-1+ Myeloid Cells
Gabrilovich, D. I., Velders, M. P., Sotomayor, E. M., & Kast, W. M. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.9.5398 · Cited by 538 · see citing works
Self-citationBronte, V., Apolloni, E., Cabrelle, A., Ronca, R., Serafini, P., Zamboni, P., Restifo, N. P., & Zanovello, P. (2000) · Blood · doi:10.1182/blood.v96.12.3838 · Cited by 527 · see citing works
Vonderheide, R. H., Flaherty, K. T., Khalil, M., Stumacher, M., Bajor, D. L., Hutnick, N. A., Sullivan, P., Mahany, J. J., Gallagher, M., Kramer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.3311 · Cited by 513 · see citing works
Self-citationKusmartsev, S. A., Cheng, F., Yu, B., Nefedova, Y., Sotomayor, E. M., Lush, R. M., & Gabrilovich, D. I. (2003) · PubMed · Cited by 460 · see citing works
Self-citationAntonia, S. J., Mirza, N., Fricke, I., Chiappori, A., Thompson, P., Williams, N., Bepler, G., Simon, G., Janssen, W., Lee, J.-H., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2013 · Cited by 444 · see citing works
Self-citationCady, S. G., & Sono, M. (1991) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(91)90142-6 · Cited by 298 · see citing works
Immature myeloid cells and cancer-associated immune suppression
Kusmartsev, S. A., & Gabrilovich, D. I. (2002) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-002-0280-8 · Cited by 297 · see citing works
Self-citationSpecht, J. M., Wang, G., Do, M. T., Lam, J. S., Royal, R. E., Reeves, M. E., Rosenberg, S. A., & Hwu, P. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.8.1213 · Cited by 294 · see citing works
Arlen, P. M., Gulley, J. L., Parker, C., Skarupa, L., Pazdur, M. P., Panicali, D., Beetham, P. K., Tsang, K. Y., Grosenbach, D. W., Feldman, J. L., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2059 · Cited by 287 · see citing works
Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation
Bodner, S. M. (1993) · Lung Cancer · doi:10.1016/0169-5002(93)90516-z · Cited by 279 · see citing works
Hopkins-Donaldson, S., Ziegler, A., Kurtz, S., Bigosch, C., Kandioler, D., Ludwig, C., Zangemeister‐Wittke, U., & Stahel, R. A. (2003) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401157 · Cited by 270 · see citing works
Clinical Responsiveness of Glioblastoma Multiforme to Chemotherapy after Vaccination
Wheeler, C. J., Das, A., Liu, G., Yu, J. S., & Black, K. L. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0497 · Cited by 266 · see citing works
Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL
Brossart, P., Goldrath, A. W., Butz, E. A., Martin, S. F., & Bevan, M. J. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.7.3270 · Cited by 264 · see citing works
Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines.
Mayordomo, J. I., Loftus, D. J., Sakamoto, H., Cesare, C. M. D., Appasamy, P. M., Lotze, M. T., Storkus, W. J., Appella, E., & DeLeo, A. B. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.183.4.1357 · Cited by 253 · see citing works
Simon, G. R., & Wagner, H. R. (2003) · CHEST Journal · doi:10.1378/chest.123.1_suppl.259s · Cited by 221 · see citing works
A common gain of function of p53 cancer mutants in inducing genetic instability
Liu, D., Song, H., & Xu, Y. (2009) · Oncogene · doi:10.1038/onc.2009.376 · Cited by 214 · see citing works
High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors
Simmons Cancer Center (1993) · Lung Cancer · doi:10.1016/0169-5002(93)90526-4 · Cited by 209 · see citing works
Tumor Eradication by Wild-type p53-specific Cytotoxic T Lymphocytes
Vierboom, M., Nijman, H. W., Offringa, R., van der Voort, E. I. H., van Hall, T., van den Broek, L., Fleuren, G. J., Kenemans, P., Kast, W. M., & Melief, C. J. M. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.5.695 · Cited by 206 · see citing works
Cancer Vaccines: Moving Beyond Current Paradigms
Schlom, J., Arlen, P. M., & Gulley, J. L. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0588 · Cited by 205 · see citing works
Nimmanapalli, R., Perkins, C. L., Орландо, М., O'Bryan, E., Nguyen, D. N., & Bhalla, K. N. (2001) · PubMed · Cited by 202 · see citing works
Gain-of-function mutations in the tumor suppressor gene p53.
van Oijen, M. G., & Slootweg, P. J. (2000) · PubMed · Cited by 193 · see citing works
A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer
Smit, E. F., Fokkema, E., Biesma, B., Groen, H. J. M., Snoek, W., & Postmus, P. E. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.54 · Cited by 190 · see citing works
High Efficiency Adenovirus-Mediated Gene Transfer to Human Dendritic Cells
Dietz, A. B., & Vuk‐Pavlović, S. (1998) · Blood · doi:10.1182/blood.v91.2.392.392_392_398 · Cited by 181 · see citing works
High Efficiency Adenovirus-Mediated Gene Transfer to Human Dendritic Cells
Dietz, A. B., & Vuk‐Pavlović, S. (1998) · Blood · doi:10.1182/blood.v91.2.392 · Cited by 169 · see citing works
Gribben, J. G., Ryan, D. P., Boyajian, R. N., Urban, R. G., Hedley, M. L., Beach, K. J., Nealon, P., Matulonis, U. A., Campos, S. M., Gilligan, T. D., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2111 · Cited by 165 · see citing works
Ribas, A., Hanson, D. C., Noe, D. A., Millham, R., Guyot, D. J., Bernstein, S. H., Canniff, P. C., Sharma, A., & Gómez-Navarro, J. (2007) · The Oncologist · doi:10.1634/theoncologist.12-7-873 · Cited by 161 · see citing works
Wan, Y., Bramson, J. L., Carter, R., Graham, F. L., & Gauldie, J. (1997) · Human Gene Therapy · doi:10.1089/hum.1997.8.11-1355 · Cited by 141 · see citing works
THOMSON, S. A., Khanna, R., Gardner, J., Burrows, S. R., Coupar, B. E. H., Moss, D. J., & Suhrbier, A. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.13.5845 · Cited by 140 · see citing works
Theobald, M., Ruppert, T., Kuckelkorn, U., Hernández, J., Häußler, A., Ferreira, E. A., Liewer, U., Biggs, J., Levine, A. J., Huber, C., et al. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.6.1017 · Cited by 117 · see citing works
Kelley, M. J., Linnoila, R. I., Avis, I. M., Georgiadis, M. S., Cuttitta, F. F., Mulshine, J. L., & Johnson, B. E. (1997) · CHEST Journal · doi:10.1378/chest.112.1.256 · Cited by 109 · see citing works
Chikamatsu, K., Nakano, K., Storkus, W. J., Appella, E., Lotze, M. T., Whiteside, T. L., & DeLeo, A. B. (1999) · PubMed · Cited by 97 · see citing works
Full-length dominant-negative survivin for cancer immunotherapy.
Писарев, В. М., Yu, B., Salup, R. R., Sherman, S., Altieri, D. C., & Gabrilovich, D. I. (2003) · PubMed · Cited by 93 · see citing works
Self-citationNikitina, E. Y., Clark, J. I., van Beynen, J., Chada, S., Virmani, A. K., Carbone, D. P., & Gabrilovich, D. I. (2001) · PubMed · Cited by 82 · see citing works
Self-citationDendritic cells transduced with wild-type p53 gene elicit potent anti-tumour immune responses
Ishida, T., Chada, S., Stipanov, M. A., Nadaf, S., Ciernik, F. I., Gabrilovich, D. I., & Carbone, D. P. (1999) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.1999.00913.x · Cited by 79 · see citing works
Self-citationCombined modality immunotherapy and chemotherapy: a new perspective
Ramakrishnan, R., Antonia, S. J., & Gabrilovich, D. I. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0531-4 · Cited by 69 · see citing works
Self-citationManagement of Small Cell Lung Cancer
Johnson, D. H. (1999) · CHEST Journal · doi:10.1378/chest.116.suppl_3.525s · Cited by 67 · see citing works
Enhancing efficacy of therapeutic vaccinations by combination with other modalities
Gulley, J. L., Madan, R. A., & Arlen, P. M. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.04.091 · Cited by 67 · see citing works
Antitumor efficacy of wild-type p53-specific CD4(+) T-helper cells.
Zwaveling, S., Vierboom, M., Mota, S. C. F., Hendriks, J. A., Ooms, M. E., Sutmuller, R. P. M., Franken, K. L. M. C., Nijman, H. W., OSSENDORP, F. A., van der Burg, S. H., et al. (2002) · PubMed · Cited by 60 · see citing works
Topotecan in the Treatment of Recurrent Small Cell Lung Cancer: An Update
Ardizzoni, A. (2004) · The Oncologist · doi:10.1634/theoncologist.9-90006-4 · Cited by 59 · see citing works
Eura, M., Chikamatsu, K., Katsura, F., Obata, A., Sobao, Y., Takiguchi, M., Song, Y., Appella, E., Whiteside, T. L., & DeLeo, A. B. (2000) · PubMed · Cited by 53 · see citing works
Nikitina, E. S., Chada, S., Muro‐Cacho, C., Fang, B., Zhang, R., Roth, J., & Gabrilovich, D. (2002) · Gene Therapy · doi:10.1038/sj.gt.3301670 · Cited by 46 · see citing works
Self-citationParadigm Shifts in Cancer Vaccine Therapy
Schlom, J., Gulley, J. L., & Arlen, P. M. (2008) · Experimental Biology and Medicine · doi:10.3181/0708-mr-226 · Cited by 46 · see citing works
Parajuli, P., Писарев, В. М., Sublet, J., Steffel, A., Varney, M. L., Singh, R. K., LaFace, D., & Talmadge, J. E. (2001) · PubMed · Cited by 45 · see citing works
Activated CD4+ T Cells Dramatically Enhance Chemotherapeutic Tumor Responses In Vitro and In Vivo
Radfar, S., Wang, Y., & Khong, H. T. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901747 · Cited by 42 · see citing works
Management of small cell lung cancer
Johnson, B. E. (2002) · Clinics in Chest Medicine · doi:10.1016/s0272-5231(03)00070-4 · Cited by 41 · see citing works
Clamon, G. H., Herndon, J., Perry, M., Ozer, H., Kreisman, H., Maher, T., Ellerton, J. A., & Green, M. R. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.4.316 · Cited by 37 · see citing works
Interferon Maintenance Therapy for Small Cell Lung Cancer: Improvement in Long-Term Survival
Mattson, K. V., Niiranen, A., Ruotsalainen, T. M., Maasilta, P. K., Halme, M. K., Pyrhönen, S. O., Kajanti, M., Mäntylä, M., Tamminen, K., Jekunen, A. P., et al. (1997) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.1997.17.103 · Cited by 35 · see citing works
Zarogoulidis, P., Ziogas, E., Papagiannis, A., Charitopoulos, K., Dimitriadis, K. S., Economides, D., Maglaveras, N., & Vamvalis, C. (1996) · Lung Cancer · doi:10.1016/0169-5002(95)00583-8 · Cited by 33 · see citing works
Treatment of recurrent small cell lung cancer
Davies, A. M., Evans, W. K., Mackay, J. A., & Shepherd, F. A. (2004) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2003.12.010 · Cited by 26 · see citing works
Combining vaccines with conventional therapies for cancer
Arlen, P. M., Madan, R. A., Hodge, J. W., Schlom, J., & Gulley, J. L. (2007) · Update on Cancer Therapeutics · doi:10.1016/j.uct.2007.04.004 · Cited by 24 · see citing works
Adjunctive interferon-alpha-2c in stage IIIB/IV small-cell lung cancer: a phase III trial
Prior, C., Oroszy, S., Oberaigner, W., Schenk, E., Kummer, F., Aigner, K., Hausmaninger, H., Peschel, C., & Huber, H. P. (1997) · European Respiratory Journal · doi:10.1183/09031936.97.10020392 · Cited by 22 · see citing works
Kast, W. M. (2000) · CRC Press eBooks · doi:10.1201/9781498713238 · Cited by 11 · see citing works
p53: A Target for T-Cell Mediated Immunotherapy
Kast, W. M. (2000) · CRC Press eBooks · doi:10.1201/9781498713238-8 · Cited by 7 · see citing works
Chiappori, A., Sereno, M., Gabrilovich, D. I., Mirza, N. N., Dunn, M. W., Janssen, W. E., Smilee, R. C., Menander, K. B., Chada, S., & Antonia, S. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.3012 · Cited by 5 · see citing works
Self-citation
Flagged first, then by citations
Research works printed but not linked: 2
- [29]Brossart P Goldrath AW Butz EA Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL J Immunol 1997 158 3270 3276 9120283
- [31]Wan Y Bramson J Carter R Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination Hum Gene Ther 1997 8 1355 1363 9295130
Cited by
Sorted by citations
Lung cancer immunotherapy: progress, pitfalls, and promises
Lahiri, A., Maji, A., Potdar, P. D., Singh, N., Parikh, P., Bisht, B., Mukherjee, A., & Paul, M. K. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01740-y · Cited by 1,102 · see citing works
Lung cancer: Biology and treatment options
Lemjabbar‐Alaoui, H., Hassan, O. U., Yang, Y., & Buchanan, P. C. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.08.002 · Cited by 1,024 · see citing works
Drugging p53 in cancer: one protein, many targets
Hassin, O., & Oren, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00571-8 · Cited by 736 · see citing works
Immune parameters affecting the efficacy of chemotherapeutic regimens
Zitvogel, L., Kepp, O., & Kroemer, G. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.223 · Cited by 665 · see citing works
Mutant p53 in cancer: from molecular mechanism to therapeutic modulation
Chen, X., Zhang, T., Su, W., Dou, Z., Zhao, D., Jin, X., Lei, H., Wang, J., Xie, X., Cheng, B., et al. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-05408-1 · Cited by 494 · see citing works
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396 · see citing works
Translating p53 into the clinic
Cheok, C. F., Verma, C. S., Baselga, J., & Lane, D. P. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.174 · Cited by 381 · see citing works
Vacchelli, E., Vitale, I., Eggermont, A. M. M., Fridman, W. H., Fucikova, J. P., Cremer, I., Galon, J., Tartour, É., Zitvogel, L., Kroemer, G., et al. (2013) · OncoImmunology · doi:10.4161/onci.25771 · Cited by 246 · see citing works
Targeting Tumor Suppressor p53 for Cancer Therapy: Strategies, Challenges and Opportunities
Hong, B., van den Heuvel, A. P. J., Prabhu, V. V., Zhang, S., & El‐Deiry, W. S. (2014) · Current Drug Targets · doi:10.2174/1389450114666140106101412 · Cited by 245 · see citing works
Anguille, S., Van de Velde, A. L., Smits, E. L., Van Tendeloo, V. F., Juliusson, G., Cools, N., Nijs, G., Stein, B., Lion, E., Van Driessche, A., et al. (2017) · Blood · doi:10.1182/blood-2017-04-780155 · Cited by 230 · see citing works
Adams, S., Kozhaya, L., Martiniuk, F. T., Meng, T., Chiriboga, L. A., Liebes, L., Hochman, T., Shuman, N., Axelrod, D., Speyer, J. L., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1149 · Cited by 223 · see citing works
Schvartsman, G., Peng, S. A., Bis, G., Lee, J. J., Benveniste, M. F. K., Zhang, J. J., Roarty, E. B., Lacerda, L., Swisher, S. G., Heymach, J. V., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.07.034 · Cited by 215 · see citing works
Therapeutic targeting of tumor suppressor genes
Morris, L. G. T., & Chan, T. A.-T. (2014) · Cancer · doi:10.1002/cncr.29140 · Cited by 201 · see citing works
Targeting the p53 signaling pathway in cancer therapy – the promises, challenges and perils
Stegh, A. H. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.643299 · Cited by 192 · see citing works
Recent Advances in p53 Research and Cancer Treatment
Suzuki, K., & Matsubara, H. (2011) · BioMed Research International · doi:10.1155/2011/978312 · Cited by 187 · see citing works
Application of Evolutionary Principles to Cancer Therapy
Enríquez‐Navas, P. M., Wojtkowiak, J. W., & Gatenby, R. A. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1337 · Cited by 175 · see citing works
Galluzzi, L., Senovilla, L., Vacchelli, E., Eggermont, A. M. M., Fridman, W. H., Galon, J., Sautès‐Fridman, C., Tartour, É., Zitvogel, L., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.21494 · Cited by 149 · see citing works
Cui, Y. R., & Guo, G. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17111942 · Cited by 135 · see citing works
The Evolution and Ecology of Resistance in Cancer TherapyPreprint
Gatenby, R. A., & Brown, J. S. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a033415 · Cited by 130 · see citing works
RetractedPirollo, K. F., Nemunaitis, J. J., Leung, P. K., Nunan, R., Adams, J., & Chang, E. H. (2016) · Molecular Therapy · doi:10.1038/mt.2016.135 · Cited by 119 · see citing works
Interactions between the tumor suppressor p53 and immune responses
Menéndez, D., Shatz, M., & Resnick, M. A. (2012) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32835b6386 · Cited by 114 · see citing works
Cancer stem cells and immunoresistance: clinical implications and solutions.
Codony‐Servat, J., & Rosell, R. (2015) · PubMed Central · doi:10.3978/j.issn.2218-6751.2015.12.11 · Cited by 112 · see citing works
Impact of Tumour Volume on the Potential Efficacy of Therapeutic Vaccines
Gulley, J. L., Madan, R. A., & Schlom, J. (2011) · Current Oncology · doi:10.3747/co.v18i3.783 · Cited by 102 · see citing works
The role of immunotherapy in small cell lung cancer
Calles, A., Aguado, G., Sandoval, C., & Alvarez, R. M. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-018-02011-9 · Cited by 101 · see citing works
Emens, L. A. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181eb5066 · Cited by 100 · see citing works
Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy
Song, B., Yang, P., & Zhang, S. (2024) · 癌症：英文版 · doi:10.1002/cac2.12520 · Cited by 97 · see citing works
SCLC–State of the Art and What Does the Future Have in Store?
Kahnert, K., Kauffmann-Guerrero, D. E., & Huber, R. M. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.05.014 · Cited by 77 · see citing works
Polymeric oncolytic adenovirus for cancer gene therapy
Choi, J.-W., Lee, Y. S., Yun, C., & Kim, S. W. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.009 · Cited by 74 · see citing works
Dendritic Cell-Based Immunotherapy in Lung Cancer
Stevens, D., Ingels, J., Lint, S. V., Vandekerckhove, B., & Vermaelen, K. Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.620374 · Cited by 71 · see citing works
Emerging biomaterial-based strategies for personalized therapeutic in situ cancer vaccines
Viswanath, D. I., Liu, H., Huston, D. P., Chua, C. Y. X., & Grattoni, A. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121297 · Cited by 69 · see citing works
Chiappori, A. A., Williams, C. C., Gray, J. E., Tanvetyanon, T., Haura, E. B., Creelan, B. C., Thapa, R., Chen, D.-T., Simon, G. R., Bepler, G., et al. (2019) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-018-2287-9 · Cited by 64 · see citing works
Self-citationPestana, R. C., Becnel, M., Rubin, M. L., Torman, D., Crespo, J., Phan, J., Hanna, E. Y., Bell, D., Glisson, B. S., Johnson, J. M., et al. (2019) · Oral Oncology · doi:10.1016/j.oraloncology.2019.104523 · Cited by 61 · see citing works
Beyond the Standard of Care: A Review of Novel Immunotherapy Trials for the Treatment of Lung Cancer
Hall, R. D., Gray, J. E., & Chiappori, A. (2013) · Cancer Control · doi:10.1177/107327481302000105 · Cited by 57 · see citing works
Self-citationWeide, B., Eigentler, T., Pflugfelder, A., Leiter, U., Meier, F. E., Bauer, J. M., Schmidt, D., Radny, P., Pföhler, C., & Garbe, C. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0957-3 · Cited by 55 · see citing works
Sweet, K. L., Hazlehurst, L., Sahakian, E., Powers, J. J., Nodzon, L., Kayali, F., Hyland, K. A., Nelson, A. M., & Pinilla-Ibarz, J. A. (2018) · Leukemia Research · doi:10.1016/j.leukres.2018.10.002 · Cited by 54 · see citing works
Soliman, H. H., Khambati, F. A., Han, H. S., Ismail-Khan, R. R., Bui, M. M., Sullivan, D. M., & Antonia, S. J. (2018) · Oncotarget · doi:10.18632/oncotarget.24118 · Cited by 54 · see citing works
Self-citationNovel therapies in small cell lung cancer.
Mamdani, H. M., Induru, R. R., & Jalal, S. I. (2015) · PubMed Central · doi:10.3978/j.issn.2218-6751.2015.07.20 · Cited by 52 · see citing works
Wu, C., Xu, Y., Yang, L., Wu, J., Zhu, W., Li, D., Cheng, Z., Xia, C., Guo, Y., Gong, Q., et al. (2015) · Advanced Functional Materials · doi:10.1002/adfm.201501031 · Cited by 51 · see citing works
Novel Therapies for Small Cell Lung Cancer
Koczywas, M., & Amanam, I. U. (2019) · Current cancer research · doi:10.1007/978-3-030-17832-1_8 · Cited by 51 · see citing works
Jadus, M. R., Natividad, J., Mai, A., Ouyang, Y. Q., Lambrecht, N. W. G., Szabó, S., Ge, L., Hoa, N. T., & Dacosta-Iyer, M. G. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/160724 · Cited by 49 · see citing works
Cancer evolution: A means by which tumors evade treatment
Zhu, X. M., Shi, L., Xu, B., & Luo, H. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.111016 · Cited by 50 · see citing works
Guo, G., & Cui, Y. R. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0053-5 · Cited by 45 · see citing works
Li, Y., Li, B., Li, C., & Li, L. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.990882 · Cited by 41 · see citing works
A new hope: the immunotherapy in small cell lung cancer
LI, Q., YUAN, D., Ma, C., LIU, Y., Ma, L., Lv, T., & Song, Y. (2016) · Neoplasma · doi:10.4149/302_151001n511 · Cited by 41 · see citing works
Role of myeloid-derived suppressor cells in metastasis
Cole, K., Pravoverov, K., & Talmadge, J. E. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09947-x · Cited by 38 · see citing works
Pharmacological Activation of p53 in Cancer Cells
Athar, M., Elmets, C. A., & Kopelovich, L. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211795222595 · Cited by 38 · see citing works
Dendritic Cells in the Pathogenesis and Treatment of Human Diseases: A Janus Bifrons?
Cools, N., Petrizzo, A., Smits, E., Buonaguro, L., Tornesello, M. L., Berneman, Z. N., & Buonaguro, L. (2011) · Immunotherapy · doi:10.2217/imt.11.110 · Cited by 36 · see citing works
Tumor–stromal interactions in lung cancer: novel candidate targets for therapeutic intervention
El-Nikhely, N. A., Larzábal, L., Seeger, W., Calvo, A., & Savai, R. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.693478 · Cited by 35 · see citing works
Lin, X., Li, W., Lai, J., Okazaki, M., Sugimoto, S., YAMAMOTO, S., Wang, X., Gelman, A. E., Kreisel, D., & Krupnick, A. S. (2012) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2012.06.02 · Cited by 34 · see citing works
Radiation and Anti-Cancer Vaccines: A Winning Combination
Cadena, A. P., Cushman, T. R., Anderson, C., Barsoumian, H. B., Welsh, J. S., & Cortez, M. A. (2018) · Vaccines · doi:10.3390/vaccines6010009 · Cited by 34 · see citing works
Next Generation Cancer Vaccines—Make It Personal!
Terbuch, A., & Lopez, J. S. (2018) · Vaccines · doi:10.3390/vaccines6030052 · Cited by 33 · see citing works
Immunotherapy in Extensive-Stage Small Cell Lung Cancer
Sayed, R. E., & Blais, N. (2021) · Current Oncology · doi:10.3390/curroncol28050347 · Cited by 32 · see citing works
Truxová, I., Hensler, M., Škapa, P., Halaška, M. J., Laco, J., Ryška, A., Spisek, R., & Fucikova, J. (2016) · International review of cytology · doi:10.1016/bs.ircmb.2016.09.003 · Cited by 31 · see citing works
The Journey of in vivo Virus Engineered Dendritic Cells From Bench to Bedside: A Bumpy Road
Goyvaerts, C., & Breckpot, K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02052 · Cited by 27 · see citing works
Modulation of immune responses by the tumor suppressor p53
Lowe, J. M., Shatz, M., Resnick, M. A., & Menéndez, D. (2013) · Biodiscovery · doi:10.7750/biodiscovery.2013.8.2 · Cited by 29 · see citing works
Development of targeted therapy and immunotherapy for treatment of small cell lung cancer
Saito, M., Shiraishi, K., Goto, A., Suzuki, H. Y., Kohno, T., & Kono, K. (2018) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyy068 · Cited by 29 · see citing works
Ding, X., Cao, H., Chen, X., Jin, H., Liu, Z., Wang, G., Cai, L., Li, D., Niu, C. S., Tian, H., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0514-0 · Cited by 28 · see citing works
Role of myeloid-derived suppressor cells in tumor recurrence
Cole, K., Al-Kadhimi, Z. S., & Talmadge, J. E. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10079-1 · Cited by 28 · see citing works
Immunological evaluation of personalized peptide vaccination in refractory small cell lung cancer
Terazaki, Y., Yoshiyama, K., Matsueda, S., Watanabe, N., Kawahara, A., Naito, Y., Suekane, S., Komatsu, N., Ioji, T., Yamada, A., et al. (2012) · Cancer Science · doi:10.1111/j.1349-7006.2012.02202.x · Cited by 24 · see citing works
Opportunities and obstacles of targeted therapy and immunotherapy in small cell lung cancer
Lin, Y., Lai, Q., Gou, L., Feng, J., & Yang, J. (2020) · Journal of drug targeting · doi:10.1080/1061186x.2020.1797050 · Cited by 24 · see citing works
p53: from understanding its structure to advances in therapeutic targeting
Wang, W., Liu, X., Liu, H., Abolhassani, H., Yan, H., Zhang, H., & Wang, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02549-5 · Cited by 25 · see citing works
Genetically modified dendritic cells in cancer immunotherapy: a better tomorrow?
Shurin, M. R., Gregory, M., Morris, J. C., & Malyguine, A. M. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2010.526105 · Cited by 22 · see citing works
Abascal, J. W., Oh, M. S., Liclican, E. L., Dubinett, S. M., Salehi‐Rad, R., & Liu, B. (2023) · Cells · doi:10.3390/cells12192404 · Cited by 21 · see citing works
Gene-modified dendritic cell vaccines for cancer
Abraham, R. S., & Mitchell, D. A. (2016) · Cytotherapy · doi:10.1016/j.jcyt.2016.09.009 · Cited by 21 · see citing works
Combining immunotherapy and radiation therapy for small cell lung cancer and thymic tumors
Patel, S. H., Rimner, A., & Cohen, R. B. (2007) · Translational Lung Cancer Research · doi:10.21037/tlcr.2017.03.04 · Cited by 21 · see citing works
Therapeutic Exploitation of Neuroendocrine Transdifferentiation Drivers in Prostate Cancer
Maylin, Z. R., Smith, C. D., Classen, A., Asim, M., Pandha, H., & Wang, Y. Z. (2024) · Cells · doi:10.3390/cells13231999 · Cited by 21 · see citing works
Technological and Therapeutic Advances in Advanced Small Cell Lung Cancer
Lum, C., & Alamgeer, M. (2019) · Cancers · doi:10.3390/cancers11101570 · Cited by 20 · see citing works
Nonreplicating Adenoviral Vectors: Improving Tropism and Delivery of Cancer Gene Therapy
Tessarollo, N. G., Domingues, A. C. M., Antunes, F., da Luz, J. C. D. S., Rodrigues, O. A., Cerqueira, O. L. D., & Strauss, B. E. (2021) · Cancers · doi:10.3390/cancers13081863 · Cited by 19 · see citing works
Neoantigen Identification and Dendritic Cell-Based Vaccines for Lung Cancer Immunotherapy
Kumari, K., Singh, A., Chaudhary, A., Singh, R. K., Shanker, A., Kumar, V., & Haque, R. (2024) · Vaccines · doi:10.3390/vaccines12050498 · Cited by 19 · see citing works
Saito, H., Kitagawa, K., Yoneda, T., Fukui, Y., Fujsawa, M., Bautista, D., & Shirakawa, T. (2017) · Cancer Gene Therapy · doi:10.1038/cgt.2017.21 · Cited by 19 · see citing works
Cellular Immunotherapy of Cancer: An Overview and Future Directions
Tao, Z., Li, S., Ichim, T. E., Yang, J., Riordan, N. H., Yenugonda, V. M., Babić, I., & Kesari, S. (2017) · Immunotherapy · doi:10.2217/imt-2016-0086 · Cited by 19 · see citing works
Cell cycle inhibitors for the treatment of NSCLC
Shcherba, M., Liang, Y., Fernandes, D. L., Perez-Soler, R., & Cheng, H. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.902935 · Cited by 18 · see citing works
Adenovirus-Based Immunotherapy of Cancer: Promises to Keep
de Gruijl, T. D., & van de Ven, R. (2012) · Advances in cancer research · doi:10.1016/b978-0-12-398342-8.00006-9 · Cited by 18 · see citing works
Zeng, M., Zhang, W., Li, Y., & Li, Y. (2024) · Biomarker Research · doi:10.1186/s40364-024-00581-1 · Cited by 17 · see citing works
Biaoxue, R., Hui, P., Wenlong, G., & Shuanying, Y. (2016) · Scientific Reports · doi:10.1038/srep39355 · Cited by 16 · see citing works
Research progress in the treatment of small cell lung cancer
Qiu, Y., Liu, Z., Yang, W., Zhao, Y., Tang, J., Tang, W., Jin, Y., Fang, L., Zhong, R., & Wang, H. (2016) · Journal of Cancer · doi:10.7150/jca.16822 · Cited by 13 · see citing works
Therapies in the pipeline for small-cell lung cancer: Table 1
Romanidou, O., Imbimbo, M., Mountzios, G., Abidin, A. Z., Morgillo, F., & Califano, R. (2016) · British Medical Bulletin · doi:10.1093/bmb/ldw022 · Cited by 13 · see citing works
Immunotherapy Exposes Cancer Stem Cell Resistance and a New Synthetic Lethality
Radvanyi, L. G. (2013) · Molecular Therapy · doi:10.1038/mt.2013.160 · Cited by 13 · see citing works
Current Development of Therapeutic Vaccines in Lung Cancer
Banda, J. S. F., Gangane, S., Raza, F., & Massarelli, E. (2025) · Vaccines · doi:10.3390/vaccines13020185 · Cited by 11 · see citing works
In Silico Model Estimates the Clinical Trial Outcome of Cancer Vaccines
Lőrincz, O., Tóth, J., Molnár, L., Miklós, I., Pántya, K., Megyesi, M., Somogyi, E., Csiszovszki, Z., & Tőke, E. R. (2021) · Cells · doi:10.3390/cells10113048 · Cited by 11 · see citing works
Immunotherapy for small cell lung cancer: the current state and future trajectories
Qiang, M., Liu, H., Yang, L., Wang, H., & Guo, R. (2024) · Discover Oncology · doi:10.1007/s12672-024-01119-5 · Cited by 9 · see citing works
Janosky, M. D., Sabado, R. L., Cruz, C. M., Vengco, I., Hasan, F., Winer, A., Moy, L. P., & Adams, S. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-014-0032-2 · Cited by 9 · see citing works
Adenovirus-Based Vectors for the Development of Prophylactic and Therapeutic Vaccines
Borovjagin, A. V., Gómez-Gutiérrez, J. G., Shirwan, H., & Matthews, Q. L. (2014) · Springer eBooks · doi:10.1007/978-3-7091-1818-4_8 · Cited by 8 · see citing works
Progress in immunotherapy for small cell lung cancer
Zhao, D., Xie, B., Yang, Y., Yan, P., Liang, S., & Lin, Q. (2020) · World Journal of Clinical Oncology · doi:10.5306/wjco.v11.i6.370 · Cited by 8 · see citing works
Prospects and Challenges of Lung Cancer Vaccines
Lin, Z., Chen, Z., Pei, L., Chen, Y., & Ding, Z. (2025) · Vaccines · doi:10.3390/vaccines13080836 · Cited by 7 · see citing works
Guo, H., He, Y., Chen, P., Wang, L., Li, W., Chen, B., Liu, Y., Wang, H., Zhao, S., & Zhou, C. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd-20-1689 · Cited by 6 · see citing works
Novel therapeutic strategies for recurrent SCLC
Moliner, L., Zhang, B., Lamberti, G., Ardizzoni, A., Byers, L. A., & Califano, R. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104017 · Cited by 7 · see citing works
Neuroendocrine cancer vaccines in clinical trials
Bridle, B. W. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.68 · Cited by 7 · see citing works
Furubayashi, N., Hori, Y., Morokuma, F., Tomoda, T., Negishi, T., Inoue, T., Kumagai, M., Kuroiwa, K., Tokuda, N., & Nakamura, M. (2021) · Molecular and Clinical Oncology · doi:10.3892/mco.2021.2253 · Cited by 7 · see citing works
Yamada, M., Tazawa, H., Suemori, K., Okada, N., Kajiwara, Y., Shoji, R., Nagai, Y., Inoue, H., Hashimoto, N., Kanaya, N., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01219-5 · Cited by 6 · see citing works
Clinical relevance and therapeutic aspects of professional antigen-presenting cells in lung cancer
Shanmugam, G., Das, S., Paul, S., Rakshit, S., & Sarkar, K. (2022) · Medical Oncology · doi:10.1007/s12032-022-01841-6 · Cited by 6 · see citing works
Small Cell Lung Cancer: Current and Future Strategies
Lampaki, S., Zarogoulidis, P., Lagoudi, K., Tsavlis, D., Kioumis, I. P., Papakala, E., Lazaridis, G., Huang, H., Hohenforst‐Schmidt, W., Pavlidis, P., et al. (2016) · Oncomedicine · doi:10.7150/oncm.16926 · Cited by 6 · see citing works
Sanaei, M., Pourbagheri‐Sigaroodi, A., Rezvani, A., Zaboli, E., Salari, S., Masjedi, M. R., & Bashash, D. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122652 · Cited by 5 · see citing works
EGFR nanovaccine in lung cancer treatment
Anggaraditya, P. B., Adiputra, P., & Widiana, I. K. (2019) · Bali Medical Journal · doi:10.15562/bmj.v8i3.1494 · Cited by 4 · see citing works
Imhof, D., Pownall, W., Schlange, C., Monney, C., Ortega‐Mora, L. M., Ojo, K. K., A, W. C. V. V., Oevermann, A., & Hemphill, A. F. (2022) · Frontiers in Veterinary Science · doi:10.3389/fvets.2022.901056 · Cited by 4 · see citing works
Dondulkar, A., Akojwar, N., Katta, C. B., Khatri, D. K., Mehra, N. K., Singh, S. B., & Madan, J. (2021) · Current Pharmaceutical Design · doi:10.2174/1381612827666211104155604 · Cited by 4 · see citing works
González‐Cao, M., Sisteré‐Oró, M., Morán, T., Reguart, N., Cabezón, R., Hernández, A. A., Román-Lladó, R., Molina‐Vila, M. Á., Birgin, K., Domenjo‐Vila, E., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2026-015351 · Cited by 2 · see citing works
Ahmed, G., Abdel-Aziz, H. O., Elsayed, H., & Adly, M. (2021) · The Egyptian Journal of Histology · doi:10.21608/ejh.2021.71195.1457 · Cited by 2 · see citing works
Ujházy, P., & Carbone, D. P. (2011) · Journal of Thoracic Oncology · doi:10.1097/01.jto.0000407570.29900.a5 · Cited by 2 · see citing works
Ding, X., Cao, H., Chen, X., Zhao, Y., Jin, H., Niu, C. S., Ma, K., Liu, Z., Chen, J., Wang, X., et al. (2016) · Journal of Cellular Immunotherapy · doi:10.1016/j.jocit.2016.02.001 · Cited by 2 · see citing works
- Authors
- Chiappori, A. A., Soliman, H., Janssen, W. E., Antonia, S. J., & Gabrilovich, D. I.
- Affiliations
- University of South Florida (US)
- Moffitt Cancer Center (US)
- Corresponding author
- Chiappori, Alberto A
- Venue
- Expert Opinion on Biological Therapy
- Publisher
- Informa UK Limited
- Published
- 2010-04-26
- Volume
- 10
- Issue
- 6
- Pages
- 983-991
- ISSN
- 1471-2598 (ISSN-L)
- 1744-7682
- PMC
- PMC3146364
- OpenAlex
- W2144694610
- Cited by
- 126
- References
- 61
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 6 · 2023: 6 · 2022: 6 · 2021: 10 · 2020: 4 · 2019: 6 · 2018: 7 · 2017: 6 · 2016: 12 · 2015: 10 · 2014: 10 · 2013: 9 · 2012: 11
- FWCI
- 4.62
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Expert Opinion on Biological Therapy (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (K24CA128953, P50CA119997)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- dendritic cell vaccine, p53, small cell lung cancer, adenoviral vector, cancer immunotherapy, chemosensitization, vaccine safety, TP53 mutation
- MeSH terms
- Animals, Dendritic Cells, Humans, Immunotherapy, Lung Neoplasms, Randomized Controlled Trials as Topic, Tumor Suppressor Protein p53, Clinical Trials, Phase I as Topic, Clinical Trials, Phase II as Topic, Cancer Vaccines, Small Cell Lung Carcinoma
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
